GlobeNewsWire
22 Nov 2026, 10:24 UTC · 1h ago
Anteris' DurAVR THV Demonstrates 1% Heart Failure Hospitalization, Single-Digit Gradients and No Valve-Related Deaths at 1 Year in Patients with Small Aortic Annuli
Impact · against what's priced in
Anteris' DurAVR THV showed exceptional 1-year clinical outcomes in a high-risk small-annuli cohort, specifically zero valve-related deaths and a 1% heart failure hospitalization rate. These results strengthen the case for FDA approval in 2027 and suggest superior competitiveness against existing TAVR options.
- ANTR+0.70
No priced-in read yet





